TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01758250

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Acoustic Radiation Force Impulse (ARFI)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Flowmetry (LDF)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Laser Doppler Perfusion Imaging (LDI)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Optical Coherence Tomography (OCT)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Orthogonal Polarization Spectral Imaging (OPSI)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)

Intervention type: OTHER
Intervention: Nail fold video capillaroscopy (NVC)
Study: NCT00797823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Asp(B28)-
Description: Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution 0.9%
Study: NCT00810979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090
Description: tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: matching tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Subjects were dosed with the statin prescribed specifically by their prescribing physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Subjects were dosed with the statin prescribed specifically by their prescribing physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Subjects were dosed with the statin prescribed specifically by their prescribing physician.
Study: NCT04420598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowe
Study: NCT01113827

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Extract
Description: Capsule form ingested 1x/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Extract
Description: Capsule form ingested 1x/day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00793481

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
Study: NCT02686593

Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine, AraC, mitoxantrone (CLAM)
Description: The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
Study: NCT00920660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25g SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: During the last treatment period, subjects will receive 30 mg open-label prednisolone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5g SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1g SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2g SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
Study: NCT02457871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Nurse Case Management
Description: The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
Study: NCT02432768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Anaplerotic dietary oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Safflower oil
Study: NCT02556255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Laser™ Atherectomy Catheter
Description: Laser atherectomy catheter based on 355 nm
Study: NCT04352439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg aspirin daily
Study: NCT02899039

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: extra blood draw samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: extra blood draw samples

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: extra blood draw samples
Study: NCT01442883

Intervention type: DEVICE
Intervention: Simplicity Catheter
Description: percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
Study: NCT00744874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF Ablation procedure
Description: Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
Study: NCT04011865

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical prostatectomy
Description: The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
Study: NCT00598416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Responsive Psychoeducation Program (PERF)
Description: Group psychoeducation for HCV patients and their primary caregiver.
Study: NCT00634829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol (Armstrong Albuterol HFA)
Description: 2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate (Provenetil-HFA)
Description: 2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-HFA
Description: Placebo containing HFA propellant without active drug substance
Study: NCT00375726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3/4delta30(ME)
Description: Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3/4delta30(ME)
Description: Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3/4delta30(ME)
Description: Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN3/4delta30(ME)
Study: NCT00288080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Premedication of dexamethasone prior to docetaxel, per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antiandrogen
Description: Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antiandrogen
Description: Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonist
Description: LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
Study: NCT01720537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose A
Description: Single SC Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose B
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose B
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 Dose A
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 Dose A
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose C
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose C
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose D
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Subcutaneous Injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose E
Description: Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05335810 Dose D
Description: Single Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single Intravenous Infusion
Study: NCT00345670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534
Description: 10:4 TCID50 of MEDI-534 intranasal spray Study Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534
Description: 10:5 TCID50 of MEDI-534 intranasal spray Study Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534
Description: 10:6 TCID50 of MEDI-534; intranasal spray
Study: NCT02435849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
Study: NCT04868084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical literacy in the early years
Description: Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
Study: NCT04099303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed
Description: 0.5 mL, Intramuscular Other Name: DTcP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Combined Vaccine, Adsorbed
Description: 2mL, Intramuscular Other Name: DT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: 0.5 mL, Intramuscular Other Name: DTaP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria-tetanus-acellular pertussis vaccine
Description: 0.5 mL, Intramuscular Other Name: DTaP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine
Description: 0.5 mL, Intramuscular Other Name: PENTAXIM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine
Description: 0.5 mL, Intramuscular Other Name: PENTAXIM
Study: NCT04440995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pectoral nerve block
Description: Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
Study: NCT01641406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
Description: ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
Description: Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
Description: ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is \>5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is \<5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
Study: NCT03636139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial DC stimulation : anodal
Description: anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial DC stimulation : sham
Description: sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
Study: NCT01251328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: general anaesthesia is performed according to the hospitals standard

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation
Description: Sedation is performed according to the hospitals standard